



(11) **EP 1 506 951 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Claims EN 9

(51) Int Cl.:
C07C 59/52 ^(2006.01) **C07D 307/84** ^(2006.01)
A61K 31/19 ^(2006.01) **A61K 31/34** ^(2006.01)
A61P 9/00 ^(2006.01)

(48) Corrigendum issued on:
26.08.2009 Bulletin 2009/35

(86) International application number:
PCT/CN2003/000375

(45) Date of publication and mention
of the grant of the patent:
04.03.2009 Bulletin 2009/10

(87) International publication number:
WO 2003/099759 (04.12.2003 Gazette 2003/49)

(21) Application number: **03732181.7**

(22) Date of filing: **21.05.2003**

(54) **METHOD FOR THE PREPARATION OF TOTAL SALVIANOLIC ACID**
VERFAHREN ZUR HERSTELLUNG VON GESAMT-SALVIANOLSÄURE
PROCEDE DE PREPARATION D'ACIDE SALVIANOLIQUE TOTALE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR

- **YE, Zhengliang**
Tianjin 300142 (CN)
- **LI, Xu**
Beichen District,
Tianjin 300402 (CN)

(30) Priority: **23.05.2002 CN 02117923**

(43) Date of publication of application:
16.02.2005 Bulletin 2005/07

(74) Representative: **Crowhurst, Charlotte Waveney et al**
Potter Clarkson LLP
Park View House
58 The Ropewalk
Nottingham
NG1 5DD (GB)

(73) Proprietor: **Tianjin Tasly Pharmaceutical Co., Ltd.**
Beichen District,
Tianjin 300402 (CN)

(72) Inventors:

- **WEI, Feng**
Beichen District,
Tianjin 300402 (CN)
- **YUE, Hongshui**
Beichen District,
Tianjin 300402 (CN)
- **LI, Dekun**
Beichen District,
Tianjin 300402 (CN)
- **SUN, Jiangxiao**
Beichen District,
Tianjin 300402 (CN)

(56) References cited:
WO-A-98/24460 **CN-A- 1 247 855**
CN-A- 1 342 638 **US-B1- 6 299 910**

- **TAKASHI TANAKA ET AL.: 'Magnesium and ammonium-potassium lithospermates B' CHEM. PHARM. BULL. vol. 37, no. 2, 1989, pages 340 - 344, XP002204927**
- **TAKAKO YOKOZAWA ET AL.: 'Isolation of the active component having the Uremia-preventive effect from Salviae Miltiorrhizae radix extract' CHEM. PHARM. BULL. vol. 36, no. 1, 1988, pages 316 - 320, XP002992806**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 506 951 B9

Description**Field of the invention**

5 [0001] The present invention relates to method for extracting total salvianolic acid from Danshen.

Background of the invention

10 [0002] Danshen, also known by its botanical name *Radix Salvia Miltiorrhizae*, is one of the most common-used traditional Chinese medicines (TCM) in China. It mainly consists of two categories of chemical ingredients, namely the water-soluble and the non water-soluble. Dating back to the early 20th century, the chief research on these ingredients has always been concentrated on the non water-soluble ones represented by tashinone, and achieved great success after decades of efforts. It is not until the beginning of 1980s that, after a lot of work, our scientists have studied Danshen's water-soluble ingredients, and first reported structure of the water-soluble one, Danshensu. Afterward, tens of water-soluble ones have also been discovered one after another with the definitive chemical structure. Subsequently it has been proven that, of the active ingredients in Danshen's water-soluble ones, the most effective is phenolic acid compounds, such as salvianoic acid A(1), B(2), C(3), D(4), E(5), F(8), G(9), H(11), I(12), J(13), rosmarinci acid (6), alkannic acid (7), isosalvianoic acid C(10), glucoside of rosmarinci acid(14), etc. (Lian-Niang Li, J. Chinese Pharmaceutical Sciences 1997, 6, 57-64). Pharmacologically, a variety of activities of these salvianolic acid compounds have already been reported. For example, Salvianolic acid A has significant protecting effects on cardiac muscle cell caused by ischemic reperfusion (I/R), and totalphenolic acid has strong anti-arrhythmia effect induced by I/R; Salvianolic acid A, B and totalphenolic acid have showed markedly protective effects against brain damage caused by I/R in rats by lowering content of MDA in brain tissues; there are plenty more other effects for the salvianolic acid as follows: anti-thrombus effects, protective effect on liver and kidney, anti-oxidation and inhibiting lipid super oxidation, as well scavenging pu-

15
20
25

30 [0003] At present, a great number of processes of extracting Salvianolic acid have been reported, but most of them are mainly focused on passing resin column following extracting by water. For example, Takashi Tanaka et al revealed the method of extracting salvianolate (Chemical Pharmaceutical Bulletin, 1989, 37 (2),340~344). Besides, there have also been many other scientists who have adopted similar methods for extracting phenolic compounds from Danshen, such as Koji Hase et al (Planta Medica, 1997, 63, 22~26), Xu Yaming et al (China patent CN1247855A, published in March, 2000), Liu Ping et al (China patent CN1270809A, published in October, 2000), and Li Lianniang (China Patent Application No. 0114228.2, filed on September 2001). But all of above-mentioned processes for extracting have a common problem in industrialization, namely a great deal of water need to be concentrated. Because of the instability, the concentrating temperature of total salvianolic acid water decoction must be varying between 50°C and 60°C, which accordingly will result in both the difficulties in techniques and rise in cost. Meanwhile, the lasting heating process, although between 50°C and 60°C, will also produce a series of serious problems including instability, and therefore affect its quality and curative effect. Finally, all these problems make it almost impossible for the industrialization. Another shortcoming of these already-existing processes is that the low yield, generally between 2% and 3%, limits its application in the industry.

35
40

Summary of the invention

45 [0004] Accordingly, one object of the present invention is, obviating the drawbacks of the prior art, to provide a method for preparation of totalphenolic acid from Danshen with high yield, low cost, good quality, and convenience of being applied in the industry. Thus, the present inventions provides a method for the preparation of total salvianolic acid according to appended Claim 1.

Detailed description of the preferred embodiments

50 [0005] The present invention of preparing totalphenolic acid mainly consists of the following steps, namely decocting Danshen with hot water; separating the decoction with Polyamide column and macroporous adsorption resin.

[0006] The totalphenolic acid may be obtained by the following scheme:

- 55 (a) After the impurities is eliminated, the Danshen is cut into little sections or pulverized into crude powder, and decocted with hot water. The decoction is filtered after its pH value being adjusted to acidity.
- (b) Applying said decoction on a polyamide column, and washing the column with water to neutral condition. Eluting the column with weak basic aqueous solution, and collecting the eluent.
- (c) Applying the eluent on the macroporous adsorption resin column, after acidifying the basic eluent of step (b). At

first, washing the column with water to neutral condition, and then eluting the column with hydrous or anhydrous lower alcohol. Afterward, collecting the eluent.

(d) Concentrating the eluent under reduced pressure until there is no ethanol, and drying it to obtain the total salviannic acid.

5

[0007] In step (a), Danshen is extracted with hot water for 2 to 4 times, 0.5 to 2h each, and the extracting temperature is 60 to 100°C, preferably 90 to 100°C; the extract solution after each extracting process, alone or combined, preferably combined, is further treated; the pH value is adjusted with acid to less than 4, preferably below 2.

10

[0008] In step (b), the concentration of weak basic aqueous solution preferably is from 0.01% to 2%, most preferably 0.08% to 0.5%, and the common polyamide materials is used, for example, polycaprolactam (nylon-6).

15

[0009] In step (c), the common macroporous adsorbent resin is used, for example styrene-type adsorbent resin; the pH value of weak basic fractions are adjusted by acid to below 4, preferably below 2; the number of carbon atoms in lower alcohol ranges from 1 to 5, for example, the methanol, ethanol, etc.; the eluting concentration is 40% to 95%, preferably 60% to 95%. However, in view of the safety in large-scale industrialized production, lowering cost and process simplification, eluting by 95% ethanol is the best option to achieve satisfying purpose.

[0010] In step (d), if necessary, said concentrate is dried, such as by lyophilization, following being filtered with microporous filter membrane.

[0011] The totalphenolic acid produced by the method of this invention can be formulated into any kind of pharmaceutically acceptable dosage form, and can also be combined with other medicaments or active ingredients.

20

[0012] Compared with the prior art, this invention has the following advantages:

1. Easiness of industrialization. In the prior art, a great deal of water need to be concentrated during the process, resulting in the difficulties in industrialization. Such a defect is overcome in the present invention, wherein, without heating and decompression, lot of water are surprisingly removed. Consequently, the processes and conditions are optimized with no energy consuming and environment pollution. So, with the advantages in respect of techniques or environmental protection, it is easy to bring about industrialization.

25

2. Reduction of loss in active ingredients. The present invention can effectively avoid a loss of active ingredients caused by precipitation with alcohol in prior art, and also prevent instability of totalphenolic acid in concentrating a lot of water. All these above would in effect avoid the losses and decomposition of the active ingredients during the process, so as to assure the stability of final product.

30

3. High yield. The yield of the products produced in the prior art (i.e. the dried totalphenolic acid powder) is only 2%-3% by weight based on the crude herbal medicine; while using the method of present invention, the yield is more than 4%, apparently better than that of the prior art. Moreover, the content of totalphenolic acid in the high quality final product is more than 80% with less impurity.

35

4. Lower cost. In the method of present invention, a great deal of water can be concentrated and removed without heating and decompression, effectively reducing the energy consumption and cost. In addition, the yield of the total phenolic acid by this invention is higher, and moreover its content in the final product is close to or higher than that of the prior art, that is to say, more products with equal or better quality will be produced from the same amount of crude herbal medicine. The lower cost will benefit a lot, not only in the industrialization, but also the patients' economic interests, accordingly bringing about a great social benefit.

40

5. The studies on animals also show the good effects of the totalphenolic acid produced by the method of present invention.

Protective effect of the totalphenolic acid against cerebral artery ischemia in rats

45

1. Materials and Methods

[0013]

50

1) Animals: Male Wister rats, weighing from 200 to 220g (Certificate No. SCXK(Beijing) 2002-003), are obtained from the Animal Center of Beijing Medical University.

2) Reagents : Chloral Hydrate purchased from Shenyang reagent factory, Liaoning, China, the batch number being 920401.

55

Red tetrazoline (TTC) from Beijing chemical plant, the batch number being 810911.

3) Apparatus: High-frequency electric knife purchased from Beijing medical electronic apparatus factory. The SXP-1B operating microscope from Shanghai medical optical instrument factory.

4) Tested agents: The total phenolic acid produced by Tianjin Tasly Modern TCM institute according to the method of the present invention; and

The total salvianolic acid produced by Institute of Materia Medica, Chinese Academy of Medical Sciences in accordance with the method of China Patent Application No. 01142288.2 filed on September, 2001.

Xiangdan injection, as control drug, purchased from Ya an Sanjiu pharmaceutical Co. Ltd, the bath number being 010901.

5) Formulation method of the tested agents and route of administration: The totalphenolic acid and Xiangdan injection are diluted into desired concentration with sterilized physiological saline, 10mg/kg and 20mg/kg for the totalphenolic acid, and 1 ml/kg (equal to 1g/kg) for Xiangdan injection. By sublingual vein, both of these kinds of drugs are administered 30 minutes after ischemia.

6) Groups: All rats are randomly divided into the following groups: sham operation control group, ischemic control group, total phenolic acid (Institute of Materia Medica) 10mg/kg and 20mg/kg groups, total phenolic acid (Tasly) 10mg/kg and 20mg/kg groups .

2. Method

[0014]

1) cerebral artery blockade (electric coagulation) ischemia in rats: Rats are anesthetized by intraperitoneal injection of Trichloroacetic aldehyde, 350mg/kg body weight, and fixed on a board in a left lateral position. Under the operating microscope, the skin is incised open via midline between the external auditory meatus and the canthus. The zygomatic orthopedics is exposed, and removed thoroughly with orthopedics rongeur. The fascia is nipped off along skull, and tempora fossa is exposed. Between the squamous orthopedics and mandible is gently propped up with retractor, and at the bottom of the skull the skull window is opened so as to uncover cerebral middle artery. The middle artery is burnt out with the high-frequency electric knife in order to block the blood flow, forming a model of cerebral local ischemia. After 30 minutes, the rats are administrated through sublingual vein, and sent back to cage for feed. The room temperature is rigorously kept between 24°C and 25°C.

2) The measurement of cerebral infarct volume: 24 hours after the cerebral middle artery is blocked, the rats are beheaded and their cerebrums are taken out. The whole cerebrum is kept at 4°C in a beaker filled with normal-saline in a refrigerator for 10 minutes, and then the olfactory bulb, the cerebellum and the low-set brain stem are removed. Along the coronal plane, the cerebrum is chipped into 5 slices, and put into 5 ml dyeing solutions containing 1.5 ml of 4% TTC and 0.1 ml of 1 mol/L di-potassium hydrogen phosphate, light-proof incubated in water bath 37°C for 30 minutes. The slices of cerebrum are taken out and put into 10% formalin for solidification. As a result, the normal cerebral tissue is rose pink, and the ischemic one is white. The weight planimetry is used to measure the area of infarct, and further the percentage of the area of infarct to the whole cerebrum hemisphere is calculated.

3) The measurement of content of water in the cerebrum: 24 hours after blockade of the cerebral middle artery, the rats are executed, and the whole cerebrum is gently taken out. After that the olfactory bulb, the cerebellum and the low-set brain stem are taken away, the cerebrum is weighed (regarded as the cerebral wet weight). After that, the cerebrum is dried in an oven at 105°C till that the weight is constant (about 48 hours), and is weighed again (referred to as the cerebral dry weight). The final content of water in the cerebrum is calculated with the following formula:

$$\frac{\text{the cerebral wet weight} - \text{the cerebral dry weight}}{\text{the cerebral wet weight}} \times 100\%.$$

3. Result

[0015] Protective effect of the totalphenolic acid against the cerebral middle artery coagulation ischemia in rats

EP 1 506 951 B9

group	dosage mg / kg	number of animal N	Volume of infarct (%)	the content of water (%)
sham operation control group		12	0	79.4586±0.3402**
ischemic control group		10	7.0194±4.389	80.4487±0.8614
Xiangdan injection	1m//kg	12	0.7553±2.2188**	79.43644±0.5061
total phenolic acid (Institute of Materia Medica)	10	12	3.2919±3.205#	79.4723±0.5475**
total phenolic acid (Institute of Materia Medica)	20	12	1.5156±2.7602*	79.4806±0.6819*
total phenolic acid (Tasly)	10	10	2.8170±3.2621#	79.4529±0.7693*
total phenolic acid (Tasly)	20	10	1.5328±3.2575*	79.5914±0.5843*

note: (1) **P<0.01, *P<0.05, two-sided test, comparing with ischemic control group.
#P<0.05, one-sided test, compared with ischemic control group.
(2) 1ml/kg the Xiang dan injection as a control is equal to 1g/kg of crude herbal medicine;
10mg/kg totalphenolic acid (Tasly) is equal to 0.25g/kg of crude herbal medicine (calculated with yield being 4%); and
20mg/kg totalphenolic acid (Tasly) is equal to 0.5g/kg of crude herbal medicine (calculated with yield being 4%).

4. Conclusion

[0016] By using the method of coagulation in middle cerebral artery to attain cerebral ischemia in rats, the protective effect of the totalphenolic acid produced respectively by Tasly and Institute of Materia Medica on cerebral artery ischemic has been observed. The result revealed that, 30 min after administration in vein, 10mg/kg and 20mg/kg of both two kinds of phenolic acids could markedly alleviate cerebral edema and cerebral infarction caused by ischemia. Moreover, the said two kinds of phenolic acids had the same effect administered in the same dosage. All above studies have showed that two phenolic acids had the same effect of anti-cerebral ischemia.

[0017] The totalphenolic acid obtained according to this invention can be formulated into pharmaceutically acceptable dosage forms, including tablet, capsule, granules, oral liquid, sustained-release formulation, control-release formulation, gel, ointment, salve, cream, suppository, injection, powder, patch, dripping pill and suspension.

[0018] The totalphenolic acid can be used for the treatment of diseases, including cardiovascular and cerebrovascular disease, nephrosis, hepatopathy, pneumonia, pneumocardial disease, pancreatitis, diabetes mellitus, cervical syndrome, ocular fundus vascular disease, ocular fundus neuro-disease, migraine, chronic gastritis, dizziness, orthopedics disease, mountain sickness and senile dementia.

Embodiments

[0019] The following examples are offered for purposes of illustration only and are not intended to limit the scope of the invention in any way.

Comparative Example

[0020] Totalphenolic acid is prepared according to the Chinese Patent Application No. 01142288.2, filed on Sept. 2001.

[0021] 5 Kg of Danshen herb is ground into crude powder, and is extracted at 100°C for three times with deionized water added, specifically, extracted for 1 hour with 30L water added the first time, and extracted for 0.5 hour with 15L water added the second and third times respectively. The extract is concentrated to 5L at 50°C under reduced pressure and cooled. Into the concentrate 14L of 95% ethanol is added. The mixture is allowed to stand over night and filtered. Under reduced pressure, the ethanol is recovered at 50°C. The obtained concentrate is applied on RA macroporous adsorption resin (mainly containing styrene and chrysophenine, and the weight of dried resin is 2kg). The resin is washed with deionized water until that the eluent had no apparent α -naphthol reaction, and then eluted with 50% ethanol until that the eluent had no obvious phenolic hydroxyl reaction with iron sesquichloride potassium ferricyanide added. The fractions are concentrated at 50°C under reduced pressure. The mixture is allowed to stand over night in a refrigerator, and filtered to produce the extract of Total salvianolic acid. The pH of the said extract is adjusted with 2% sodium hydroxid to 6.5, and the extract is freeze dried to produce 114g of totalphenolic acid. The yield of the final product in crude drug is 2.3%. The analysis showed that the content of totalphenolic acid in final product amounted to 83.72%, and Salvianolic

EP 1 506 951 B9

acid B was in amount of 54.41%.

[0022] Total salvianolic acid and Salvianolic acid B are analyzed according to the method of Chinese Patent Application No. 01142288.3 filed on Sep. 2001.

- 5 (1) Salvianolic acid B: analyzed by HPLC at 288 nm. The Salvianolic acid B CRS is manufactured by Modern TCM Institute under Tianjin Tasly Group with purity of 98.0%.
(2) Total salvianolic acid: Content= F (A-B) + B

10 wherein, A is the content of Total salvianolic acid calculated with the Salvianolic acid B as CRS by ultraviolet spectrophotometry;
B is the content of Salvianolic acid B by HPLC;
F is correction factor 0.626.

EXAMPLE 1

15 **[0023]** 5 kg of Danshen herb is ground into crude powder, and is extracted at 100°C at the state of lightly boiling for three times with deionized water, specifically, extracted for 1 hour with water (x5.5 fold) added the first time, and extracted for 0.5 hour with water (x3 fold) added the second and third times respectively. The extract is combined, and the pH thereof is adjusted with 10% hydrochloric acid to 2.0. The extract is filtered, and the filtrate is loaded on polyamide column (the amount of the dry resin is two-thirds of that of the crude herb). The column is washed with deionized water (x5 fold), and the washing is discarded. Then the column is eluted with 5 column volumes of the 0.1% aqueous solution of sodium bicarbonate. The fraction was collected, adjusted with 10% hydrochloric acid to pH 2.0, and is loaded on D₁₀, macro-porous resin column. The column is washed with deionized water to neutral condition and the washing is discarded. Then the column is eluted with 95% ethanol, and the colored belt is collected when it is eluted down. The fractions are concentrated under reduced pressure to entire dryness. The above concentrate is dissolved with water. The mixture is allowed to stand over night in refrigerator, and filtered by 0.3 μm mixed cellulose microporous membrane to produce extraction solution of Total salvianolic acid. Immediately after this totalphenolic acid is adjusted with 2% sodium hydroxide to pH 6.0, it is freeze dried to produce 221g of freeze-dried powders of Total salvianolic acid. The yield of the final product is 4.4% based on the amount of the crude herb. The analysis according to the method of Chinese Patent Application No. 01142288.2 filed on Sep. 2001 shows that, the totalphenolic acid amounts to 83.94%, and Salvianolic acid B is 53.73% in the final product.

Example 2

35 **[0024]** 5 kg of Danshen herb is ground into crude powder, and is extracted at 80°C for three times with deionized water, specifically, extracted for 2 hours with water (x5.5 fold) added the first time, and extracted for 1 hour with water (x3 fold) added the second and third times respectively. The extracts are combined, and the pH thereof is adjusted with 5% sulfuric acid to 1. The extract is filtered, and the filtrate is loaded on polyamide column (the amount of the dry resin is two-thirds of that of the crude herb). The column is washed with deionized water (x5 fold), and the washing is discarded. Then the column is eluted with 4 column volumes of the 0.2% aqueous solution of sodium bicarbonate. The fractions are collected, adjusted with 5% sulfuric acid to a pH of 1, and is loaded on AB-8 macro-porous adsorption resin column. The column is washed with deionized water to neutral condition and the washing is discarded. Then the column is eluted with 60% ethanol, and the colored belt is collected when it is eluted down. The fractions are concentrated under the reduced pressure until it had no smell of ethanol. The mixture is allowed to stand over night in refrigerator, and filtered by 0.3 μm mixed cellulose micro-porous membrane to produce extraction solution of Total salvianolic acid. Immediately after this totalphenolic acid is adjusted with 2% sodium hydroxide to pH 6.0, it is freeze dried to produce 227g of freeze-dried powders of Total salvianolic acid. The yield of the final product is 4.5% based on the amount of the crude herb. The analysis according to the method of Chinese Patent Application No. 01142288.2 filed on Sep. 2001 shows that, the totalphenolic acid amounts to 83.15%, and Salvianolic acid B is 54.03% in the final product.

EXAMPLE 3

50 **[0025]** 5 kg of Danshen herb is ground into crude powder, and is extracted at 100°C at the state of lightly boiling for three times with deionized water, specifically, extracted for 1 hour with water (x5.5 fold) added the first time, and extracted for 0.5 hour with water (x3 fold) added the second and third times respectively. The extract is combined, and the pH thereof is adjusted with 10% hydrochloric acid to 2.0. The extract is filtered, and the filtrate is loaded on polyamide column (the amount of the dry resin is two-thirds of that of the crude herb). The column is washed with deionized water (x5 fold), and the washing is discarded. Then the column is eluted with 5 column volumes of the 0.1% aqueous solution

EP 1 506 951 B9

of sodium bicarbonate. The fractions are collected, adjusted with 10% hydrochloric acid to a pH of 2.0, and is loaded on RA macro-porous resin column. The column is washed with deionized water to neutral condition and the washing is discarded. Then the column is eluted with 60% Methanol, and the colored belt is collected when it is eluted down. The fractions are concentrated under the reduced pressure until it had no smell of ethanol. The mixture is allowed to stand over night in refrigerator, and filter by 0.3 μ m mixed cellulose micro-porous membrane to produce extraction solution of Total salvianolic acid. Immediately after this totalphenolic acid is adjusted with 2% sodium hydroxide to pH 6.0, it is freeze dried to produce 224g of freeze-dried powders of Total salvianolic acid. The yield of the final product is 4.5% based on the amount of the crude herb. The analysis according to the method of Chinese Patent Application No. 01142288.2 filed on Sep. 2001 shows that, the totalphenolic acid amounts to 84.02%, and Salvianolic acid B is 54.17% in the final product.

EXAMPLE 4

Formula of Total salvianolic acid capsule

[0026]

Total salvianolic acid	240g
Microcrystalline cellulose	40g
Talcum powder	1.4%
3% ethanol solution of polyvidone	appropriate
1000 capsules are produced.	

[0027] Total salvianolic acid and microcrystalline cellulose are mixed thoroughly. 3% ethanol solution of polyvidone is added into the mixture to make soft stuff. It is sifted through 18-mesh screen sieve to give granules, and dried at 60°C for 30 to 45 min. Then, talcum powder is added, and the mixture is stirred and filled into No. 1 capsule shell to produce capsules each of which contains 240mg.

EXAMPLE 5

Formula of of Total salvianolic acid tablet

[0028]

Total salvianolic acid	240g
Microcrystalline cellulose	40g
Talcum powder	1.4%
3% ethanol solution of polyvidone	appropriate
1000 tablets are produced.	

[0029] Total salvianolic acid and microcrystalline cellulose are mixed thoroughly. 3% ethanol solution of polyvidone is added into the mixture to make soft stuff. It is sifted through 18-mesh screen sieve to give granules, and dried at 60°C for 30 to 45 min. Then, talcum powders are added, and the mixture is stirred and tableted.

EXAMPLE 6

Formula of Total salvianolic acid granula

[0030]

Total salvianolic acid	240g
Microcrystalline cellulose	40g
Talcum powder	1.4%
3% ethanol solution of polyvidone	appropriate
500 sachets are produced.	

[0031] Total salvianolic acid and microcrystalline cellulose are mixed thoroughly. 3% ethanol solution of polyvidone is added into the mixture to make soft stuff. It is sifted through 18-mesh screen sieve to give granules, and dried at 60°C for 30 to 45 min, and filled into sachets.

5 EXAMPLE 7

Formula of Total salvianolic acid powder for injection

10 **[0032]**

Total salvianolic acid	100g
Mannite	30g
Antallin	5g
Distilled water	5ml

15 **[0033]** The above ingredients are mixed well, lyophilized, and filled into 1000 vials.

20 **Claims**

1. A method for the preparation of total salvianolic acid comprising the steps of:
 - a. Extracting Danshen with water and acidifying the extract and filtrating;
 - 25 b. Applying said Danshen extract on a polyamide column, washing the column with water to neutral condition, discarding the washings, eluting the polyamide column with weak basic aqueous solution, and collecting the fractions;
 - c. Applying the basic fractions of step (b) on a macroporous adsorption resin column of styrene type, after acidifying the fractions, firstly washing the column with water to neutral condition, discarding the washings, and then eluting the column with hydrous or anhydrous lower alcohol; the eluent being collected, concentrated under reduced pressure until no alcohol, and dried.
2. The method as recited in claim 1, wherein the heating extraction in step (a) by water is repeated for 2-4 times, and for 0.5~2h each.
- 35 3. The method as recited in claim 1, wherein the temperature for the said extraction of step (a) by water is 60~100°C.
4. The method as recited in claim 1, wherein the temperature for the said extraction of step (a) by water is 90~100°C.
- 40 5. The method as recited in claim 1, wherein the said extract of step (a) is adjusted with an acid to a pH value of below 4, and the basic fractions of step (c) is acidified with an acid to a pH value of below 4.
6. The method as recited in claim 1, wherein the said extract of step (a) is acidified with an acid to a pH value of below 2, and the basic fractions of step (c) is acidified with hydrochloric acid or sulfuric acid to a pH value of below 2.
- 45 7. The method as recited in claim 1, wherein in step (b) 0.01~2% of aqueous weak basic solution is used as eluant.
8. The method as recited in claim 1, wherein in step (b) 0.08~0.5% of aqueous solution of sodium hydrogen carbonate is used as eluant.
- 50 9. The method as recited in claim 1, wherein the hydrous or anhydrous lower C₁~C₅ alcohol is used as the eluant in the step (c).
10. The method as recited in claim 1, wherein in the step (c) the column is eluted with aqueous ethanol with a concentration of 40~95%.
- 55 11. The method as recited in claim 9 or 10, wherein the concentration of the lower C₁~C₅ alcohol or the aqueous ethanol is 60~95%.

12. The method as recited in claim 10, wherein the concentration of the aqueous ethanol is 95%.

Patentansprüche

- 5
1. Verfahren zum Herstellen von Gesamt-Salvianolsäure, umfassend die Schritte
- 10 a) Extrahieren von Danshen mit Wasser und Ansäuern des Extrakts und Filtrierens;
 (b) Aufbringen des Danshen-Extrakts auf eine Polyamidsäule, Waschen der Säule mit Wasser bis zum neutralen Zustand, Wegwerfen der Waschlösungen, Eluieren der Polyamidsäule mit schwacher, basischer, wässriger Lösung und Auffangen der Fraktionen;
 (c) Aufbringen der basischen Fraktionen aus Schritt (b) auf eine makroporöse Adsorptionsharzsäule des Styroltyps, nach Ansäuern der Fraktionen zuerst Waschen der Säule mit Wasser bis zum neutralen Zustand, Wegwerfen der Waschlösungen und dann Eluieren der Säule mit wässrigem oder wasserfreiem niederem Alkohol, wobei das Elutionsmittel aufgefangen, unter reduziertem Druck bis kein Alkohol vorhanden ist konzentriert, und getrocknet wird.
- 15
2. Verfahren nach Anspruch 1, wobei die Erhitzungsextraktion in Schritt (a) durch Wasser 2 - 4-mal und jeweils 0,5 - 2 h lang wiederholt wird.
- 20
3. Verfahren nach Anspruch 1, wobei die Temperatur für die Extraktion des Schritts (a) durch Wasser 60 - 100 °C beträgt.
4. Verfahren nach Anspruch 1, wobei die Temperatur für die Extraktion des Schritts (a) durch Wasser 90 - 100 °C beträgt.
- 25
5. Verfahren nach Anspruch 1, wobei der Extrakt aus Schritt (a) mit einer Säure auf einen pH-Wert unter 4 eingestellt wird und die basischen Fraktionen des Schritts (c) mit einer Säure auf einen pH-Wert unter 4 eingestellt werden.
- 30
6. Verfahren nach Anspruch 1, wobei der Extrakt aus Schritt (a) mit einer Säure auf einen pH-Wert unter 2 angesäuert wird und die basischen Fraktionen des Schritts (c) mit Salzsäure oder Schwefelsäure auf einen pH-Wert unter 2 angesäuert werden.
7. Verfahren nach Anspruch 1, wobei in Schritt (b) 0,01 - 2 % wässrige, schwache, basische Lösung als Elutionsmittel verwendet wird.
- 35
8. Verfahren nach Anspruch 1, wobei in Schritt (b) 0,08 - 0,5 % wässrige Lösung von Natriumhydrogencarbonat als Elutionsmittel verwendet wird.
9. Verfahren nach Anspruch 1, wobei der wässrige oder wasserfreie niedere C₁- ~ C₅-Alkohol in Schritt (c) als Elutionsmittel verwendet wird.
- 40
10. Verfahren nach Anspruch 1, wobei in Schritt (c) die Säule mit wässrigem Ethanol in einer Konzentration von 40 - 95 % eluiert wird.
- 45
11. Verfahren nach Anspruch 9 oder 10, wobei die Konzentration des niederen C₁- ~ C₅-Alkohols oder des wässrigen Ethanols 60 - 95 % beträgt.
12. Verfahren nach Anspruch 10, wobei die Konzentration des wässrigen Ethanols 95 % beträgt.

Revendications

- 50
1. Procédé pour la préparation d'acide salvianolique total, comprenant les étapes consistant :
- 55 a. à extraire du Danshen avec de l'eau et à acidifier l'extrait et filtrer ;
 b. à appliquer ledit extrait de Danshen sur une colonne de polyamide, laver la colonne avec de l'eau jusqu'à une condition neutre, écarter les produits de lavage, éluer la colonne de polyamide avec une solution aqueuse basique faible, et à recueillir les fractions ;
 c. à appliquer les fractions basiques de l'étape (b) sur une colonne de résine d'adsorption macroporeuse de

EP 1 506 951 B9

type styrène, après avoir acidifié les fractions, laver d'abord la colonne avec de l'eau jusqu'à une condition neutre, écarter les produits de lavage puis à éluer la colonne avec un alcool inférieur hydraté ou anhydre ; l'éluant étant recueilli, concentré sous pression réduite jusqu'à disparition de l'alcool, et séché.

- 5
2. Procédé selon la revendication 1, dans lequel l'extraction dans l'étape (a) par de l'eau en chauffant est répétée 2-4 fois, et pendant 0,5-2 h chacune.
3. Procédé selon la revendication 1, dans lequel la température pour ladite extraction de l'étape (a) par de l'eau est de 60-100 °C.
- 10
4. Procédé selon la revendication 1, dans lequel la température pour ladite extraction de l'étape (a) par de l'eau est de 90-100 °C.
- 15
5. Procédé selon la revendication 1, dans lequel ledit extrait de l'étape (a) est ajusté avec un acide jusqu'à une valeur de pH inférieure à 4, et les fractions basiques de l'étape (c) sont acidifiées avec un acide jusqu'à une valeur de pH inférieure à 4.
- 20
6. Procédé selon la revendication 1, dans lequel ledit extrait de l'étape (a) est acidifié avec un acide jusqu'à une valeur de pH inférieure à 2, et les fractions basiques de l'étape (c) sont acidifiées avec de l'acide chlorhydrique ou de l'acide sulfurique jusqu'à une valeur de pH inférieure à 2.
7. Procédé selon la revendication 1, dans lequel, dans l'étape (b), on utilise 0,01-2 % de la solution aqueuse basique faible en tant qu'éluant.
- 25
8. Procédé selon la revendication 1, dans lequel, dans l'étape (b), on utilise 0,08-0,5 % d'une solution aqueuse de bicarbonate de sodium en tant qu'éluant.
9. Procédé selon la revendication 1, dans lequel l'alcool inférieur en C₁-C₅ hydraté ou anhydre est utilisé en tant qu'éluant dans l'étape (c).
- 30
10. Procédé selon la revendication 1, dans lequel, dans l'étape (c), la colonne est éluee avec de l'éthanol aqueux ayant une concentration de 40-95 %.
- 35
11. Procédé selon la revendication 9 ou 10, dans lequel la concentration de l'alcool inférieur en C₁-C₅ ou de l'éthanol aqueux est de 60-95 %.
- 40
12. Procédé selon la revendication 10, dans lequel la concentration de l'éthanol aqueux est de 95 %.
- 45
- 50
- 55

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- CN 1247855 A [0003]
- CN 1270809 A [0003]
- CN 0114228 [0003]
- CN 01142288 [0013] [0020] [0022] [0023] [0024] [0025]

Non-patent literature cited in the description

- **LIAN-NIANG LI, J.** *Chinese Pharmaceutical Sciences*, 1997, vol. 6, 57-64 [0002]
- **DU GUANHUA et al.** *Basic medical science and clinics*, 2000, vol. 20 (5), 10-14 [0002]
- *Chemical Pharmaceutical Bulletin*, 1989, vol. 37 (2), 340-344 [0003]
- **KOJI HASE et al.** *Planta Medica*, 1997, vol. 63, 22-26 [0003]